The Diabetic Foot Ulcers drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Foot Ulcers. Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued products.
GlobalData tracks 73 drugs in development for Diabetic Foot Ulcers by 69 companies/universities/institutes. The top development phase for Diabetic Foot Ulcers is preclinical with 22 drugs in that stage. The Diabetic Foot Ulcers pipeline has 71 drugs in development by companies and two by universities/ institutes. Some of the companies in the Diabetic Foot Ulcers pipeline products market are: Biofilm Pharma, Ceria Therapeutics and MediWound.
The key targets in the Diabetic Foot Ulcers pipeline products market include Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), TNF Receptor Associated Factor 6 (E3 Ubiquitin Protein Ligase TRAF6 or Interleukin 1 Signal Transducer or RING Finger Protein 85 or TRAF6 or EC 6.3.2.), and Bacterial Cell Membrane.
The key mechanisms of action in the Diabetic Foot Ulcers pipeline product include Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Activator with two drugs in Phase I. The Diabetic Foot Ulcers pipeline products include 21 routes of administration with the top ROA being Topical and ten key molecule types in the Diabetic Foot Ulcers pipeline products market including Small Molecule, and Cell Therapy.
Diabetic Foot Ulcers overview
Diabetic foot ulcers are sores that occur on the feet of people with type 1 and type 2 diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg; pain; walking with difficulty; black, blue, or red discoloration of the feet; cold feet; and fever, skin redness, or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity, and history of tobacco use disorder.
For a complete picture of Diabetic Foot Ulcers’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
